Protalix (PLX -3.7%) slips after being downgraded to Market Perform at Wells Fargo, citing the...

|About: Protalix BioTherapeutics, Inc (PLX)|By:, SA News Editor

Protalix (PLX -3.7%) slips after being downgraded to Market Perform at Wells Fargo, citing the CHMP's rejection of Elelyso - despite the drug's favorable benefits - in deference to Shire's Orphan exclusivity status for Vpriv. The firm also lowers its price range to $6 - $8 from $9 - $11.